OPTEL conducting pilot project with Oxford University Hospitals

OPTEL signs agreement with Oxford University Hospitals to pilot their Certa decommissioning solution.

Quebec City, Canada — (HealthTech Wire / News) OPTEL GROUP, a leading global provider of traceability systems for the pharmaceutical, medical device, and healthcare industries, announced today that it has signed an agreement to pilot OPTEL’s Certa decommissioning solution at Oxford University Hospitals (OUH) to enable the world-renowned institution to comply with the European Union’s Falsified Medicines Directive (FMD).

This legislation states that, by February 9, 2019, European hospitals and retail pharmacies will be required to verify and decommission all prescription medications using their unique identifier before distributing them to patients.

This pilot project is extremely important for the healthcare industry because it will help define how hospital management teams can use this requirement to improve patient safety. In addition, it will be a concrete example of how this legislative change really affects hospital pharmacy operations and how these changes can improve operational efficiency roadmaps. “This is a massive opportunity to streamline processes and attain our ultimate goal of closed-loop medication management. It’s a key step in ensuring that we meet the WHO's Third Global Patient Safety Challenge: Medication Without Harm and that patients are given the safest possible care,” declares Mr. Bhulesh Vadher, Clinical Director of Pharmacy & Medicines Management at Oxford University Hospitals NHS Foundation Trust.

Bernard Naughton, a clinical pharmacist and researcher of falsified and counterfeit drugs, agrees with this perspective adding that: “There are a number of different actions that need to be aligned to meet the February 2019 FMD deadline; however, the solutions and processes implemented for FMD compliance will also present great benefits both in terms of workflow operations and patient safety.”

The project builds upon the evidence recently published by Naughton et al. in the BMJ OPEN journal and is significant in that it can act as a case study to help identify, implement and validate the most effective way to decommission the high volume of medications that go in and out of hospital pharmacies on an annual basis in a safe and simple manner.

“Legislations like these represent a turning point in the healthcare industry, and this project can help evaluate user adoption and determine best practices for compliance in real-world scenarios,” mentions Korina Fischer, Vice-President, Healthcare at OPTEL GROUP. “We are extremely pleased and honored that Oxford University Hospitals, one of the best research hospitals in the world, chose to collaborate with OPTEL, and we look forward to working with them on this,” concludes Ms. Fischer. 

For more information on OPTEL’s new offering, visit www.optelhealthcare.com.

Contacts:


Korina Fischer, Vice-President, Healthcare

OPTEL GROUP

Tel.: 418 688-0334, ext. 6520

korina.fischer@optelgroup.com

 

Ken Fallu, Marketing Director

OPTEL GROUP

Tel.: 418 688-0334, ext. 6113

ken.fallu@optelgroup.com

OPTEL Group

Leading provider of traceability solutions for the healthcare industry since 1989, OPTEL has taken its commitment closer to people by extending its expertise and technologies to hospitals and retail pharmacies. OPTEL partners with key industry stakeholders, assisting them throughout the healthcare supply chain ─ from the factory to the patient.

2680 Boulevard du Parc Technologique
Ville de Québec, QC G1P 4S6
Canada

Related News

PMI Health Group automates data capture using a Kodak i4600 production scanner and PSIGEN Software solution

Seizing the opportunity: how can we make the most of the Technology Fund?

Ordnance Survey's intelligent geographic information leads the way to better healthcare